ANI Pharmaceuticals receives FDA approval to expand ILUVIEN label for chronic non-infectious uveitis

ANI PHARMACEUTICALS INC

FDA approved ILUVIEN for chronic non-infectious uveitis affecting posterior segment (NIU-PS), expanding beyond DME.
ANI plans to market ILUVIEN under the combined label in the U.S. later this year.
Extended supply agreement with Siegfried through 2029; equipment upgrade and capacity expansion planned.
ILUVIEN is already approved for both DME and NIU-PS in 17 European countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.